Evidence map›Paper›PMID 27022441›Full record

ArticleWorld journal of stem cells2016

Updates in the pathophysiological mechanisms of Parkinson's disease: Emerging role of bone marrow mesenchymal stem cells.

Hanaa H Ahmed, Ahmed M Salem, Hazem M Atta, Emad F Eskandar, Abdel Razik H Farrag, Mohamed A Ghazy, Neveen A Salem, Hadeer A Aglan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of stem cells, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Hanaa H AhmedHanaa H Ahmed, Emad F Eskandar, Hadeer A Aglan, Hormones Department, Medical Research Division, National Research Centre, Giza 12622, Egypt.
Ahmed M SalemHanaa H Ahmed, Emad F Eskandar, Hadeer A Aglan, Hormones Department, Medical Research Division, National Research Centre, Giza 12622, Egypt.
Hazem M AttaHanaa H Ahmed, Emad F Eskandar, Hadeer A Aglan, Hormones Department, Medical Research Division, National Research Centre, Giza 12622, Egypt.
Emad F EskandarHanaa H Ahmed, Emad F Eskandar, Hadeer A Aglan, Hormones Department, Medical Research Division, National Research Centre, Giza 12622, Egypt.
Abdel Razik H FarragHanaa H Ahmed, Emad F Eskandar, Hadeer A Aglan, Hormones Department, Medical Research Division, National Research Centre, Giza 12622, Egypt.
Mohamed A GhazyHanaa H Ahmed, Emad F Eskandar, Hadeer A Aglan, Hormones Department, Medical Research Division, National Research Centre, Giza 12622, Egypt.
Neveen A SalemHanaa H Ahmed, Emad F Eskandar, Hadeer A Aglan, Hormones Department, Medical Research Division, National Research Centre, Giza 12622, Egypt.
Hadeer A AglanHanaa H Ahmed, Emad F Eskandar, Hadeer A Aglan, Hormones Department, Medical Research Division, National Research Centre, Giza 12622, Egypt.
National Research Centre · EGAin Shams University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo explore the approaches exerted by mesenchymal stem cells (MSCs) to improve Parkinson's disease (PD) pathophysiology.

methodsMSCs were harvested from bone marrow of femoral bones of male rats, grown and propagated in culture. Twenty four ovariectomized animals were classified into 3 groups: Group (1) was control, Groups (2) and (3) were subcutaneously administered with rotenone for 14 d after one month of ovariectomy for induction of PD. Then, Group (2) was left untreated, while Group (3) was treated with single intravenous dose of bone marrow derived MSCs (BM-MSCs). SRY gene was assessed by PCR in brain tissue of the female rats. Serum transforming growth factor beta-1 (TGF-β1), monocyte chemoattractant protein-1 (MCP-1) and brain derived neurotrophic factor (BDNF) levels were assayed by ELISA. Brain dopamine DA level was assayed fluorometrically, while brain tyrosine hydroxylase (TH) and nestin gene expression were detected by semi-quantitative real time PCR. Brain survivin expression was determined by immunohistochemical procedure. Histopathological investigation of brain tissues was also done.

resultsBM-MSCs were able to home at the injured brains and elicited significant decrease in serum TGF-β1 (489.7 ± 13.0 vs 691.2 ± 8.0, P < 0.05) and MCP-1 (89.6 ± 2.0 vs 112.1 ± 1.9, P < 0.05) levels associated with significant increase in serum BDNF (3663 ± 17.8 vs 2905 ± 72.9, P < 0.05) and brain DA (874 ± 15.0 vs 599 ± 9.8, P < 0.05) levels as well as brain TH (1.18 ± 0.004 vs 0.54 ± 0.009, P < 0.05) and nestin (1.29 ± 0.005 vs 0.67 ± 0.006, P < 0.05) genes expression levels. In addition to, producing insignificant increase in the number of positive cells for survivin (293.2 ± 15.9 vs 271.5 ± 15.9, P > 0.05) expression. Finally, the brain sections showed intact histological structure of the striatum as a result of treatment with BM-MSCs.

conclusionThe current study sheds light on the therapeutic potential of BM-MSCs against PD pathophysiology via multi-mechanistic actions.

Indexed as

Anti-apoptotic effectAnti-inflammatory actionBone marrow derived mesenchymal stem cellsNeurogenic potentialOvariectomyParkinson’s diseasePathophysiologyRotenone

Identifiers

PMID27022441
PMCPMC4807309
OpenAlexW2313796202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.